EndyMed Medical has ranked Number One on Fastest Growing Biotech/ Pharmaceutical Sector and number 25 among all Deloitte's Technology Fast 500 EMEA 2013, ranking of the 500 fastest growing technology companies in EMEA. Rankings are based on percentage revenue growth over five years.  EndyMed Medical grew 4217 per cent during this period.

EndyMed Medical's CEO, Uzi Blumensohn, credits EndyMed's revolutionary 3DEEP RF treatment technology and tremendous determination to become a major entity in the extremely competitive medical aesthetics market with the company’s 4217 per cent revenue growth over the past five years. He said, "We are very proud to be ranked first in our sector on the Deloitte Technology Fast 500 EMEA 2013. It's a great achievement, recognizing the complete dedication and exceptional hard work of the management and staff of EndyMed over the past five years. We started with a conviction that our proprietary 3DEEP technology would revolutionize the aesthetic radiofrequency treatment market, and we succeeded in making a name for ourselves in the industry."

"Making the Deloitte Technology Fast 500 is commendable in today’s highly competitive technology industry," said David Halstead, Deloitte United Kingdom, partner in charge of the Deloitte Technology Fast 500 EMEA program. "We congratulate EndyMed Medical on being one of the 500 fastest growing technology companies in the region."

“Achieving sustained revenue growth of 4217 per cent over five years is a tremendous achievement,” said David Halstead, Deloitte United Kingdom and partner in charge of the Deloitte Technology Fast 500 EMEA programme. “EndyMed Medical’s phenomenal growth puts it in select company.”

The Technology Fast 500 list is compiled from the Deloitte EMEA Technology Fast 50 programmes, nominations submitted directly to the Technology Fast 500, and public company database research. To qualify for the Technology Fast 500, entrants must have had base-year operating revenues of at least €50,000 and current-year operating revenues of at least €800,000.

Entrants must also be public or private companies headquartered in EMEA and must be a “technology company,” defined as a company that develops or owns proprietary technology that contributes to a significant portion of the company's operating revenues; or manufactures a technology-related product; or devotes a high percentage of effort to the research and development of technology. Using other companies' technology in a unique way does not qualify.

EndyMed Medical Ltd., offers energy based aesthetic treatment systems for the professional markets. EndyMed's proprietary 3DEEP radiofrequency technology is a unique solution for fractional and non-ablative wrinkle treatment, skin tightening on both the face and body, body contouring and acne scar treatment.

The Deloitte Technology Fast 500 EMEA programme is the region’s most objective industry-ranking to focus on the technology field, recognizing technology companies that have achieved the fastest rates of revenue growth in Europe, the Middle East, and Africa (EMEA) during the past five years.

Deloitte refers to one or more of Deloitte Touche Tohmatsu Limited, a UK private company limited by guarantee, and its network of member firms, each of which is a legally separate and independent entity.